Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue
27 August 2022 (12:15 - 13:00)
Organised by:
Abstract
Slides
About the speaker
National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)
6 More presentations in this session
Associate Professor M. Schmidt (Aarhus, DK)
Mrs N. Nouhravesh (Durham, US)
Mr E. Fort (Barcelona, ES)
Access the full session
The Event
ESC Congress 2022
27 August 2022
12:15 CET
